Oncotalks | Powered by Novartis

QoL improved or was maintained with Kisqali in M7 and M3, do we have any evidence of this?

Kisqali Channel
Share this item

Dr. Elisabetta Munzone is speaking on "QoL improved or was maintained with Kisqali in M7 and M3, do we have any evidence of this?"

Related items

Talking about QoL, Kisqali also improved work productivity in M7, is that unique for Kisqali ?

Talking about QoL, Kisqali also improved work productivity in M7, is that unique for Kisqali ?

Dr. Joanna Kufel-Grabowska is discussing on "When talking about QoL, Kisqali also improved work productivity in M7, is that unique for Kisqali?"

Kisqali Channel

00:03:08

ESMO 2020: Dr. Peter Fasching: Pooled analysis of PRO of QOL in M2, M3 and M7

ESMO 2020: Dr. Peter Fasching: Pooled analysis of PRO of QOL in M2, M3 and M7

Dr. Peter Fasching speaking on "Pooled analysis of PRO of QOL in M2, M3 and M7"

ESMO

00:03:30

In M3 trial, when used in 1 Line Kisqali showed PFS of 33.4m, one of the highest ever seen with a CDK4/6 inhibitor. What is your thought on this?

In M3 trial, when used in 1 Line Kisqali showed PFS of 33.4m, one of the highest ever seen with a CDK4/6 inhibitor. What is your thought on this?

Dr. Grazia Arpino is sharing her thoughts "In M3 trial, when used in 1 Line Kisqali showed PFS of 33.4m, one of the highest ever seen with a CDK4/6 inhibitor."

Kisqali Channel

00:02:23

Monaleesa-3 clinical trial also included de novo patients and this is unique among studies with CDK4/6 inhibitors + fulvestrant?

Monaleesa-3 clinical trial also included de novo patients and this is unique among studies with CDK4/6 inhibitors + fulvestrant?

Dr. Tanja Fehm is discussing on "Monaleesa-3 clinical trial also included de novo patients and this is unique among studies with CDK4/6 inhibitors + fulvestrant?"

Kisqali Channel

00:02:25

Does the use of Kisqali delay time to chemotherapy (in M3 trial)? And which numbers should we remember?

Does the use of Kisqali delay time to chemotherapy (in M3 trial)? And which numbers should we remember?

Professor Janice Walshe is discussing "Does the use of Kisqali delays time to chemotherapy (in M3 trial) ? And which numbers should we remember?"

Kisqali Channel

00:01:42

Can you describe more into depth the hormone resistant patient population included in M3 trial?

Can you describe more into depth the hormone resistant patient population included in M3 trial?

Professor Mario Campone is describing more into depth the hormone resistant patient population included in M3 trial.

Kisqali Channel

00:03:54